<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Tryptophan Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Tryptophan Res</journal-id>
<journal-id journal-id-type="publisher-id">International Journal of Tryptophan Research</journal-id>
<journal-title-group>
<journal-title>International Journal of Tryptophan Research : IJTR</journal-title>
</journal-title-group>
<issn pub-type="epub">1178-6469</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28659716</article-id>
<article-id pub-id-type="pmc">5476425</article-id>
<article-id pub-id-type="doi">10.1177/1178646917713491</article-id>
<article-id pub-id-type="publisher-id">10.1177_1178646917713491</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rodriguez Cetina Biefer</surname>
<given-names>Hector</given-names>
</name>
<xref ref-type="aff" rid="af1-10.1177_1178646917713491">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vasudevan</surname>
<given-names>Anju</given-names>
</name>
<xref ref-type="aff" rid="af2-10.1177_1178646917713491">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elkhal</surname>
<given-names>Abdallah</given-names>
</name>
<xref ref-type="aff" rid="af3-10.1177_1178646917713491">3</xref>
<xref ref-type="corresp" rid="c1-10.1177_1178646917713491"></xref>
</contrib>
</contrib-group>
<aff id="af1-10.1177_1178646917713491"><label>1</label>Department of Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland.</aff>
<aff id="af2-10.1177_1178646917713491"><label>2</label>Angiogenesis and Brain Development Laboratory, Division of Basic Neuroscience, McLean Hospital and Harvard Medical School, Belmont, MA, USA.</aff>
<aff id="af3-10.1177_1178646917713491"><label>3</label>Division of Transplant Surgery and Transplantation Surgery Research Laboratory, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA.</aff>
<author-notes>
<corresp id="c1-10.1177_1178646917713491">CORRESPONDING AUTHOR: Abdallah Elkhal, Division of Transplant Surgery and Transplantation Surgery Research Laboratory, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA. Email: <email>aelkhal@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>6</month>
<year>2017</year>
</pub-date>
<volume>10</volume>
<elocation-id>1178646917713491</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>4</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder>
<license license-type="open-access">
<license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Increasing evidence underscores the interesting ability of tryptophan to regulate immune responses. However, the exact mechanisms of tryptophan’s immune regulation remain to be determined. Tryptophan catabolism via the kynurenine pathway is known to play an important role in tryptophan’s involvement in immune responses. Interestingly, quinolinic acid, which is a neurotoxic catabolite of the kynurenine pathway, is the major pathway for the <italic>de novo</italic> synthesis of nicotinamide adenine dinucleotide (NAD+). Recent studies have shown that NAD+, a natural coenzyme found in all living cells, regulates immune responses and creates homeostasis via a novel signaling pathway. More importantly, the immunoregulatory properties of NAD+ are strongly related to the overexpression of tryptophan hydroxylase 1 (Tph1). This review provides recent knowledge of tryptophan and NAD+ and their specific and intriguing roles in the immune system. Furthermore, it focuses on the mechanisms by which tryptophan regulates NAD+ synthesis as well as innate and adaptive immune responses.</p>
</abstract>
<kwd-group>
<kwd>Nicotinamide adenine dinucleotide</kwd>
<kwd>NAD+</kwd>
<kwd>immune responses</kwd>
<kwd>tryptophan</kwd>
<kwd>kynurenine pathway</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Tryptophan was initially discovered by Hopkins and Cole in 1901 after isolation from casein protein.<xref ref-type="bibr" rid="b1-10.1177_1178646917713491">1</xref> Tryptophan is 1 of the 8 essential amino acids that cannot be synthesized by the human body.<xref ref-type="bibr" rid="b2-10.1177_1178646917713491">2</xref> Although tryptophan has the lowest concentration in the body of all the essential amino acids, only very low concentrations are required for healthy nutrition.<xref ref-type="bibr" rid="b2-10.1177_1178646917713491">2</xref> Tryptophan has been extensively studied due to its important metabolic functions, which include the synthesis of hormones such as kynurenine, serotonin, tryptamine, melatonin, and essential coenzymes, particularly nicotinamide adenine dinucleotide (NAD<sup>+</sup>), that are known to play critical physiological functions.<xref ref-type="bibr" rid="b2-10.1177_1178646917713491">2</xref>,<xref ref-type="bibr" rid="b3-10.1177_1178646917713491">3</xref></p>
<p>Tryptophan has been associated with several clinical disorders. Historically, tryptophan was associated with pellagra, a dermatological condition associated with deficiency in tryptophan and niacin.<xref ref-type="bibr" rid="b4-10.1177_1178646917713491">4</xref>,<xref ref-type="bibr" rid="b5-10.1177_1178646917713491">5</xref> Most notably, tryptophan is involved in behavioral changes through synthesis of serotonin and tryptamine, 2 major players in neuropsychiatric disorders.<xref ref-type="bibr" rid="b2-10.1177_1178646917713491">2</xref>,<xref ref-type="bibr" rid="b6-10.1177_1178646917713491">6</xref> Tryptophan deprivation induces depression, separation anxiety,<xref ref-type="bibr" rid="b7-10.1177_1178646917713491">7</xref>,<xref ref-type="bibr" rid="b8-10.1177_1178646917713491">8</xref> chronic fatigue syndrome, and fibromyalgia. Furthermore, increasing evidence shows the role of tryptophan in brain tumor pathogenesis<xref ref-type="bibr" rid="b9-10.1177_1178646917713491">9</xref>,<xref ref-type="bibr" rid="b10-10.1177_1178646917713491">10</xref> and other cancer types, such as colorectal, breast, and bladder cancers.<xref ref-type="bibr" rid="b7-10.1177_1178646917713491">7</xref>,<xref ref-type="bibr" rid="b11-10.1177_1178646917713491">11</xref>–<xref ref-type="bibr" rid="b13-10.1177_1178646917713491">13</xref></p>
<p>Interestingly, tryptophan deprivation also sensitizes activated T-cells to apoptosis <italic>in novo</italic><xref ref-type="bibr" rid="b14-10.1177_1178646917713491">14</xref> and favors the induction of regulatory T-cells (Tregs) via dendritic cells.<xref ref-type="bibr" rid="b15-10.1177_1178646917713491">15</xref>,<xref ref-type="bibr" rid="b16-10.1177_1178646917713491">16</xref> Although the role of tryptophan in regulating the immune system has been previously described,<xref ref-type="bibr" rid="b17-10.1177_1178646917713491">17</xref> research in this area has been scarce until recently. Several recent publications highlighted the involvement of tryptophan in inflammation, immune activation, and immune tolerance,<xref ref-type="bibr" rid="b11-10.1177_1178646917713491">11</xref>,<xref ref-type="bibr" rid="b13-10.1177_1178646917713491">13</xref>,<xref ref-type="bibr" rid="b18-10.1177_1178646917713491">18</xref>–<xref ref-type="bibr" rid="b20-10.1177_1178646917713491">20</xref> raising awareness of tryptophan catabolism and its role in the immune system.</p>
<p>Kynurenine is an important biosynthetic pathway in tryptophan catabolism.<xref ref-type="bibr" rid="b21-10.1177_1178646917713491">21</xref> Moreover, most of the immunologic function accredited to tryptophan was attributed to the kynurenine pathway.<xref ref-type="bibr" rid="b3-10.1177_1178646917713491">3</xref>,<xref ref-type="bibr" rid="b18-10.1177_1178646917713491">18</xref>,<xref ref-type="bibr" rid="b22-10.1177_1178646917713491">22</xref>,<xref ref-type="bibr" rid="b23-10.1177_1178646917713491">23</xref> More importantly, the kynurenine pathway is essential for the <italic>de novo</italic> synthesis of NAD<sup>+24</sup> and acts as a substrate for several other molecules.<xref ref-type="bibr" rid="b25-10.1177_1178646917713491">25</xref>,<xref ref-type="bibr" rid="b26-10.1177_1178646917713491">26</xref> Of note, the NAD<sup>+</sup> levels have been described as very volatile; therefore, the <italic>de novo</italic> synthesis of NAD<sup>+</sup> plays an important role in maintaining adequate NAD<sup>+</sup> levels.<xref ref-type="bibr" rid="b27-10.1177_1178646917713491">27</xref> Quinolinic acid (QUIN), a product of tryptophan degradation, was found to be essential for <italic>de novo</italic> synthesis of NAD<sup>+</sup> and may serve as a precursor of NAD<sup>+</sup> in the tryptophan/kynurenine pathway. Although QUIN is neurotoxic,<xref ref-type="bibr" rid="b9-10.1177_1178646917713491">9</xref>,<xref ref-type="bibr" rid="b22-10.1177_1178646917713491">22</xref>,<xref ref-type="bibr" rid="b28-10.1177_1178646917713491">28</xref> recent publications have underscored the capacity of NAD<sup>+</sup> to regulate T-cell fate and promote homeostasis<xref ref-type="bibr" rid="b29-10.1177_1178646917713491">29</xref>–<xref ref-type="bibr" rid="b31-10.1177_1178646917713491">31</xref> independent of the classical pathways that have considered cytokine environment and transcription factors as the major regulator of CD4<sup>+</sup> T-cell differentiation and adaptive immune response.</p>
<p>The kynurenine pathway is initiated by 2 rate-limiting enzymes: indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), which are essential in tryptophan catabolism. Indoleamine 2,3-dioxygenase has been found in many immune cells, such as dendritic cells (DCs) and macrophages,<xref ref-type="bibr" rid="b32-10.1177_1178646917713491">32</xref>,<xref ref-type="bibr" rid="b33-10.1177_1178646917713491">33</xref> whereas TDO has been found in the liver and neurons.<xref ref-type="bibr" rid="b32-10.1177_1178646917713491">32</xref> Moreover, both IDO<xref ref-type="bibr" rid="b34-10.1177_1178646917713491">34</xref> and TDO<xref ref-type="bibr" rid="b11-10.1177_1178646917713491">11</xref> are present in several malignancies such as prostate, colorectal, pancreatic, and breast cancers. Increasing evidence points toward an important role of IDO in the regulation of the immune system.<xref ref-type="bibr" rid="b12-10.1177_1178646917713491">12</xref>,<xref ref-type="bibr" rid="b17-10.1177_1178646917713491">17</xref>,<xref ref-type="bibr" rid="b35-10.1177_1178646917713491">35</xref> Interestingly, IDO is involved in the activation of the protein aryl hydrocarbon receptor (AhR),<xref ref-type="bibr" rid="b32-10.1177_1178646917713491">32</xref> a ligand-activated transcription factor that regulates the immune system and inflammatory responses.<xref ref-type="bibr" rid="b36-10.1177_1178646917713491">36</xref>–<xref ref-type="bibr" rid="b38-10.1177_1178646917713491">38</xref> Indeed, on activation, AhR can promote the differentiation of type 1 regulatory cells (Tr1)<xref ref-type="bibr" rid="b39-10.1177_1178646917713491">39</xref>,<xref ref-type="bibr" rid="b40-10.1177_1178646917713491">40</xref> and control Treg/T<sub>H</sub>17 differentiation,<xref ref-type="bibr" rid="b37-10.1177_1178646917713491">37</xref>,<xref ref-type="bibr" rid="b41-10.1177_1178646917713491">41</xref> critical CD4<sup>+</sup> T-cell subsets involved in immunosuppression or pro-inflammatory responses. Furthermore, IDO promotes long-term tolerance by DCs through transforming growth factor β (TGF-β) in a noninflammatory context <italic>in novo</italic>.<xref ref-type="bibr" rid="b42-10.1177_1178646917713491">42</xref>,<xref ref-type="bibr" rid="b43-10.1177_1178646917713491">43</xref></p>
<p>Collectively, these findings indicate the existence of other pathways that regulate the immune system. These alternative pathways play key roles in a myriad of diseases and may serve as an alternative to develop novel therapeutic approaches. In this mini-review, we discuss the current knowledge of the increasing evidence of tryptophan and its role in immune regulation, with an overview of the kynurenine/QUIN/NAD<sup>+</sup> pathway and emphasize missing links for which more research is needed. We also discuss possible models and key players in immune regulation via the kynurenine/QUIN/NAD<sup>+</sup> pathway.</p>
</sec>
<sec>
<title>Tryptophan and Its Role in Immune Responses</title>
<p>Tryptophan has been implicated in many metabolic processes, including the metabolic synthesis of major proteins, such as kynurenine, serotonin, tryptamine, melatonin, and other coenzymes, particularly NAD/NADP (NAD phosphate).<xref ref-type="bibr" rid="b2-10.1177_1178646917713491">2</xref> Although these metabolic processes are critical, the role of tryptophan in the immune system is still poorly understood.</p>
<p>The kynurenine pathway is a major route for the catabolism of tryptophan and has an important role in the immune system.<xref ref-type="bibr" rid="b17-10.1177_1178646917713491">17</xref>,<xref ref-type="bibr" rid="b21-10.1177_1178646917713491">21</xref>,<xref ref-type="bibr" rid="b32-10.1177_1178646917713491">32</xref>,<xref ref-type="bibr" rid="b44-10.1177_1178646917713491">44</xref> The kynurenine pathway is initiated by cleavage of the indole ring, which is initiated by tryptophan 2,3-dioxygenase 2 (TDO-2), indoleamine 2,3-dioxygenase 1 (IDO-1), or IDO-2, which shares similarities with IDO-1 but has limited catabolic activity compared with TDO-2 and IDO-1.<xref ref-type="bibr" rid="b22-10.1177_1178646917713491">22</xref>,<xref ref-type="bibr" rid="b45-10.1177_1178646917713491">45</xref>–<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref> TDO-2 has been found primarily in the liver and central nervous system (CNS), but recent publications have identified TDO-2 in different types of cancer.<xref ref-type="bibr" rid="b10-10.1177_1178646917713491">10</xref>,<xref ref-type="bibr" rid="b23-10.1177_1178646917713491">23</xref> TDO-2 suppresses antitumor immune responses and promotes tumor cell survival.<xref ref-type="bibr" rid="b48-10.1177_1178646917713491">48</xref> Furthermore, TDO-2 promotes metastasis in breast cancer<xref ref-type="bibr" rid="b49-10.1177_1178646917713491">49</xref>,<xref ref-type="bibr" rid="b50-10.1177_1178646917713491">50</xref> and the progression of lung cancer in vivo.<xref ref-type="bibr" rid="b51-10.1177_1178646917713491">51</xref> Moreover, enzymatically active TDO-2 is overexpressed in a significant proportion of human tumors.<xref ref-type="bibr" rid="b10-10.1177_1178646917713491">10</xref> TDO-2 overexpression has been correlated with poor prognosis in high-grade gliomas.<xref ref-type="bibr" rid="b45-10.1177_1178646917713491">45</xref> Current immunosuppressive therapies aim to inhibit TDO-2.<xref ref-type="bibr" rid="b11-10.1177_1178646917713491">11</xref> Pilotte et al<xref ref-type="bibr" rid="b10-10.1177_1178646917713491">10</xref> were able to restore the ability to reject TDO-expressing tumors using a self-developed TDO-inhibitor (compound 680C91). Furthermore, Crosignani et al<xref ref-type="bibr" rid="b52-10.1177_1178646917713491">52</xref> presented their preclinical assessment of a TDO-2-inhibitor (iTeos) in the 29th Annual Meeting of the Society for Immunotherapy Cancer, with similar results on a p815 mastocytoma tumor model overexpressing TDO-2.</p>
<p>Contrary to TDO-2, IDO-1 is found extrahepatically and is present in several immune cells.<xref ref-type="bibr" rid="b35-10.1177_1178646917713491">35</xref>,<xref ref-type="bibr" rid="b53-10.1177_1178646917713491">53</xref>,<xref ref-type="bibr" rid="b54-10.1177_1178646917713491">54</xref> Indeed, IDO-1 is present in human tumor cells and can prevent tumor cell rejection due to a lack of accumulation of specific T-cells.<xref ref-type="bibr" rid="b34-10.1177_1178646917713491">34</xref> Moreover, IDO-1 is upregulated by several pro-inflammatory molecules.<xref ref-type="bibr" rid="b55-10.1177_1178646917713491">55</xref>,<xref ref-type="bibr" rid="b56-10.1177_1178646917713491">56</xref> The interaction between IDO-1 and DCs has been the most studied to date. The rapid switch in function from immunogenic to tolerogenic activity is dependent on IFN-γ, whereas the tolerogenic phenotype is conferred by IDO-1. Indeed, IFN-γ is a potent activator of gene expression and enzymatic activity of IDO-1.<xref ref-type="bibr" rid="b57-10.1177_1178646917713491">57</xref>,<xref ref-type="bibr" rid="b58-10.1177_1178646917713491">58</xref> The tolerogenic phenotype induced by IDO-1 plays a double role in immune responses. Indoleamine 2,3-dioxygenase expands human CD4<sup>+</sup>CD25<sup>high</sup>Foxp3<sup>+</sup> Tregs by promoting maturation of DCs.<xref ref-type="bibr" rid="b59-10.1177_1178646917713491">59</xref> Second, IDO-expressing DCs suppressed allograft rejection by expansion of CD4<sup>+</sup>CD25<sup>high</sup>Foxp3<sup>+</sup> Tregs.<xref ref-type="bibr" rid="b33-10.1177_1178646917713491">33</xref> In contrast, IDO promotes tolerance toward tumor cells and can promote resistance toward immunotherapies.<xref ref-type="bibr" rid="b60-10.1177_1178646917713491">60</xref> More importantly, tumors expressing Foxp3<sup>+</sup>/IDO<sup>+</sup> are associated with more advanced disease.<xref ref-type="bibr" rid="b44-10.1177_1178646917713491">44</xref> Interestingly, therapies targeting IDO have been shown to be effective against different types of cancer by measuring messenger RNA.<xref ref-type="bibr" rid="b12-10.1177_1178646917713491">12</xref>,<xref ref-type="bibr" rid="b61-10.1177_1178646917713491">61</xref>,<xref ref-type="bibr" rid="b62-10.1177_1178646917713491">62</xref> Similar interactions between IDO and other cells of the immune system have been described. Among these immune cells, we found interactions with macrophages,<xref ref-type="bibr" rid="b54-10.1177_1178646917713491">54</xref>,<xref ref-type="bibr" rid="b63-10.1177_1178646917713491">63</xref> mast cells,<xref ref-type="bibr" rid="b32-10.1177_1178646917713491">32</xref>,<xref ref-type="bibr" rid="b42-10.1177_1178646917713491">42</xref> and Tregs.<xref ref-type="bibr" rid="b64-10.1177_1178646917713491">64</xref>,<xref ref-type="bibr" rid="b65-10.1177_1178646917713491">65</xref></p>
<p>The initial activation models for the kynurenine pathway showed a redundant activation through TDO-2 and IDO-1.<xref ref-type="bibr" rid="b22-10.1177_1178646917713491">22</xref> However, present evidence suggests specific roles for each of these enzymes in the tryptophan catabolic pathway. As Puccetti notes, in the early events of systemic inflammation, cortisol induces the release of acute phase proteins such as TDO-2. TDO-2 release activates the AhR, as explained below, transcribing interleukin (IL)-10 and IDO-1. Finally, the transcription of IL-10 and IDO-1 will create homeostasis.<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref> This model indicates different gene activation processes and roles for TDO-2 and IDO-1.<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref>,<xref ref-type="bibr" rid="b66-10.1177_1178646917713491">66</xref></p>
</sec>
<sec>
<title>Immune Implications of the AhR and Tryptophan Catabolic Enzymes</title>
<p>We have recently shown that kynurenine was able to promote mast cell activation by activating the AhR.<xref ref-type="bibr" rid="b32-10.1177_1178646917713491">32</xref> As previously reported, activation of AhR has been linked to activation of Tr1 and to control of Tregs and T<sub>H</sub>17 differentiation.<xref ref-type="bibr" rid="b39-10.1177_1178646917713491">39</xref>–<xref ref-type="bibr" rid="b41-10.1177_1178646917713491">41</xref> Interestingly, most immune cells—T-cells, B cells, macrophages, DCs, and natural killer cells—express AhR.<xref ref-type="bibr" rid="b67-10.1177_1178646917713491">67</xref> These findings suggest an important role of AhR in regulation of the immune system.</p>
<p>AhR is a transcription factor in the cytosol that is activated on ligand binding.<xref ref-type="bibr" rid="b67-10.1177_1178646917713491">67</xref>,<xref ref-type="bibr" rid="b68-10.1177_1178646917713491">68</xref> AhR is a key regulator of xenobiotic toxicity, such as 2,3,7,8,9-tetracholodibenzo-<italic>p</italic>-dioxin (TCDD) and dioxin, the most prominent member of the environmental pollutants.<xref ref-type="bibr" rid="b36-10.1177_1178646917713491">36</xref>,<xref ref-type="bibr" rid="b67-10.1177_1178646917713491">67</xref> However, AhR has also been identified as a key player in several signaling cascades and other cell biological events. Most likely, one of the most interesting and newly identified aspects of AhR is its involvement in immune regulation and tolerance.</p>
<p>AhR has been shown to regulate CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs as well as T<sub>H</sub>17 cell fate, which are 2 major subsets of the adaptive immune system; extensive studies have underscored the importance of Tregs and T<sub>H</sub>17 cell balance.<xref ref-type="bibr" rid="b69-10.1177_1178646917713491">69</xref>–<xref ref-type="bibr" rid="b71-10.1177_1178646917713491">71</xref> Indeed, Tregs are responsible for homeostasis and immune tolerance and are very robust immunosuppressive cells, whereas T<sub>H</sub>17 cells are considered to be pro-inflammatory cells involved in a myriad of diseases including autoimmunity.<xref ref-type="bibr" rid="b72-10.1177_1178646917713491">72</xref>,<xref ref-type="bibr" rid="b73-10.1177_1178646917713491">73</xref> Interestingly, AhR has been found to control Tregs and T<sub>H</sub>17 cell differentiation in experimental autoimmune encephalomyelitis (EAE),<xref ref-type="bibr" rid="b41-10.1177_1178646917713491">41</xref> which are the most commonly used experimental model for multiple sclerosis. In this study, the authors found that AhR activation by TCDD controls Treg development in vivo, suppressing the severity of EAE. Furthermore, activation of AhR via another ligand, 6-formylindolo 3,2-b carbazole (FICZ), increased T<sub>H</sub>17 differentiation, thereby increasing the severity of EAE.<xref ref-type="bibr" rid="b41-10.1177_1178646917713491">41</xref> Interestingly, FICZ has been shown to control Tregs via the activation of epidermal DCs when keratinocytes were exposed to UV-B light.<xref ref-type="bibr" rid="b74-10.1177_1178646917713491">74</xref> Indeed, UV-B light activation of AhR is believed to generate FICZ in the skin.<xref ref-type="bibr" rid="b75-10.1177_1178646917713491">75</xref> FICZ and TCDD have shown exert different effects on T<sub>H</sub>17/Treg development either in vitro or in vivo.<xref ref-type="bibr" rid="b76-10.1177_1178646917713491">76</xref> It is now clear that AhR modulates the immune system in response to ligands of diverse origin.<xref ref-type="bibr" rid="b37-10.1177_1178646917713491">37</xref> Furthermore, AhR ligands affect several pathways and responses depending on the tissue/cellular context.<xref ref-type="bibr" rid="b36-10.1177_1178646917713491">36</xref> There is a range of potential physiological ligands for AhR.<xref ref-type="bibr" rid="b77-10.1177_1178646917713491">77</xref> However, the exact molecular mechanisms remain elusive and are subject of current research.</p>
<p>The role of AhR as a mediator of homeostasis and immune tolerance is further supported by its involvement in the regulation of type 1 Tregs (Tr1). Tr1 cells have the capacity to coproduce IFN-γ and IL-10<xref ref-type="bibr" rid="b30-10.1177_1178646917713491">30</xref>,<xref ref-type="bibr" rid="b78-10.1177_1178646917713491">78</xref> and have emerged as an important immunosuppressive CD4<sup>+</sup> T-cell subset that dampens inflammatory responses, promotes transplant tolerance, and prevents tissue damage.<xref ref-type="bibr" rid="b29-10.1177_1178646917713491">29</xref>,<xref ref-type="bibr" rid="b79-10.1177_1178646917713491">79</xref>,<xref ref-type="bibr" rid="b80-10.1177_1178646917713491">80</xref> Gandhi et al<xref ref-type="bibr" rid="b40-10.1177_1178646917713491">40</xref> observed induction of Tr1 cells by activation of AhR through TCDD in human cells. Interestingly, in the same study, they found that adding TGF-β1 to the activation of AhR through TCDD induced functional Tregs.<xref ref-type="bibr" rid="b40-10.1177_1178646917713491">40</xref> Independent of the type of regulatory cell that is activated, AhR activation through TCDD induces a significantly higher expression of IL-10 in human cells.<xref ref-type="bibr" rid="b40-10.1177_1178646917713491">40</xref> Simultaneously, Apetoh and Quintana<xref ref-type="bibr" rid="b39-10.1177_1178646917713491">39</xref> corroborated the findings from Gandhi. Furthermore, they showed that AhR interacts with c-Maf, a transcription factor shown to regulate synthesis of IL-10,<xref ref-type="bibr" rid="b81-10.1177_1178646917713491">81</xref> to contribute to Tr1-cell differentiation.<xref ref-type="bibr" rid="b39-10.1177_1178646917713491">39</xref> The high expression of IL-10 could protect animals from EAE. Tullius et al<xref ref-type="bibr" rid="b29-10.1177_1178646917713491">29</xref> and Wang et al<xref ref-type="bibr" rid="b31-10.1177_1178646917713491">31</xref> have also shown that IL-10 is capable of promoting homeostasis and protecting from EAE via the direct activation of Tr1 cells.</p>
<p>As previously mentioned, the metabolites generated from the tryptophan/IDO/TDO pathway act as ligands for AhR.<xref ref-type="bibr" rid="b67-10.1177_1178646917713491">67</xref> Indeed, the IDO-1/AhR interaction appears to be a more effective pathway for 2 main reasons: it is self-regulated because AhR presides over the regulatory proteolysis of IDO-1, and it acts in a feed-forward loop initiated by kynurenine, followed by AhR activation, promoting IDO-1 transcription.<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref> Interestingly, the IDO-1/AhR axis is very dependent on the presence or absence IL-6, an essential pro-inflammatory cytokine for the induction of T<sub>H</sub>17 cells, and it can be antagonized by IL-10.<xref ref-type="bibr" rid="b82-10.1177_1178646917713491">82</xref></p>
<p>The absence of IL-6 is paramount for the IDO-1/AhR axis to be effective in IL-10 production and to create homeostasis.<xref ref-type="bibr" rid="b36-10.1177_1178646917713491">36</xref> However, in the early phases of inflammation, IL-6 is required as an initial defense mechanism.<xref ref-type="bibr" rid="b83-10.1177_1178646917713491">83</xref>,<xref ref-type="bibr" rid="b84-10.1177_1178646917713491">84</xref> During the early phase of inflammation, the source of kynurenine must be from somewhere other than the IDO-1/AhR axis.<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref> Once the IDO-1/AhR axis is started through an external kynurenine source, AhR can repress IL-6 via the transcription of IL-10.<xref ref-type="bibr" rid="b36-10.1177_1178646917713491">36</xref> An interesting model suggested by Puccetti indicates cortisol as an outsource for kynurenine through TDO-2.<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref> Cortisol is released with pro-inflammatory cytokines in the early phases of inflammation and releases acute phase proteins by the liver, one of which is TDO-2.<xref ref-type="bibr" rid="b47-10.1177_1178646917713491">47</xref>,<xref ref-type="bibr" rid="b48-10.1177_1178646917713491">48</xref>,<xref ref-type="bibr" rid="b85-10.1177_1178646917713491">85</xref> Interestingly, clinical trials indicated that cortisol and IL-6 increased the percentages of Tregs.<xref ref-type="bibr" rid="b84-10.1177_1178646917713491">84</xref> Furthermore, both cortisol and IL-6 can produce high amounts of TDO-2 by the liver activating the kynurenine pathway.<xref ref-type="bibr" rid="b86-10.1177_1178646917713491">86</xref> Indeed, other sources for the activation of AhR might be involved in this process and warrant further investigation.</p>
</sec>
<sec>
<title>Immunoregulatory Properties of NAD<sup>+</sup> and Tryptophan</title>
<p>The major catabolic pathway of tryptophan is the kynurenine pathway, which ultimately leads to biosynthesis of NAD<sup>+</sup>,<xref ref-type="bibr" rid="b18-10.1177_1178646917713491">18</xref> a vital cofactor that can rewire metabolism, activate sirtuins, and maintain mitochondrial fitness.<xref ref-type="bibr" rid="b87-10.1177_1178646917713491">87</xref></p>
<p>Nicotinamide adenine dinucleotide was originally discovered by Sir Arthur Harden and his colleagues in 1906.<xref ref-type="bibr" rid="b88-10.1177_1178646917713491">88</xref> However, its key role in hydrogen transfer in biochemical reactions was not discovered until 1935.<xref ref-type="bibr" rid="b87-10.1177_1178646917713491">87</xref> Nicotinamide adenine dinucleotide plays an important role in energy metabolism, but the roles of NAD<sup>+</sup> have expanded beyond its initial function as a coenzyme linking cellular metabolism to several signaling and transcriptional events.<xref ref-type="bibr" rid="b27-10.1177_1178646917713491">27</xref>,<xref ref-type="bibr" rid="b29-10.1177_1178646917713491">29</xref>,<xref ref-type="bibr" rid="b30-10.1177_1178646917713491">30</xref>,<xref ref-type="bibr" rid="b87-10.1177_1178646917713491">87</xref>,<xref ref-type="bibr" rid="b89-10.1177_1178646917713491">89</xref>,<xref ref-type="bibr" rid="b90-10.1177_1178646917713491">90</xref></p>
<p>One of the most interesting newly discovered roles of NAD<sup>+</sup> is probably its involvement in homeostasis and immune responses. Data increasingly support the notion of NAD<sup>+</sup>-regulating immune responses. For example, NAD<sup>+</sup> regulates cytokine production of peripheral blood lymphocytes and monocytes.<xref ref-type="bibr" rid="b91-10.1177_1178646917713491">91</xref>,<xref ref-type="bibr" rid="b92-10.1177_1178646917713491">92</xref> Based on these findings, we investigated the role of NAD<sup>+</sup> and T-cells. We found that intraperitoneal injections of NAD<sup>+</sup> protected mice against autoimmune diseases and prolonged allograft survival after skin transplantation.<xref ref-type="bibr" rid="b29-10.1177_1178646917713491">29</xref>,<xref ref-type="bibr" rid="b30-10.1177_1178646917713491">30</xref> In our studies, NAD<sup>+</sup> induced a systemic increase in IL-10 despite the reduction in Tregs and increase in T<sub>H</sub>17 cells. The increased IL-10 production was mediated via the immunosuppressive Tr1 cells. Moreover, NAD<sup>+</sup> induced T-cell differentiation, despite the cytokine milieu and well-established transcription factors. Interestingly, a genome-wide gene expression profile assessed by microarray analysis showed tryptophan hydroxylase 1 (Tph1) to be upregulated under the influence of NAD<sup>+</sup>, mostly described on mast cells. Collectively, our data indicate NAD<sup>+</sup> as a potent immune regulator through tryptophan catabolism.</p>
<p>Several publications have indicated a strong relation between NAD<sup>+</sup> and tryptophan, particularly with the kynurenine pathway.<xref ref-type="bibr" rid="b27-10.1177_1178646917713491">27</xref>,<xref ref-type="bibr" rid="b89-10.1177_1178646917713491">89</xref>,<xref ref-type="bibr" rid="b93-10.1177_1178646917713491">93</xref>,<xref ref-type="bibr" rid="b94-10.1177_1178646917713491">94</xref> Furthermore, NAD<sup>+</sup> is essential for cells under physiological stress to avoid cell damage.<xref ref-type="bibr" rid="b17-10.1177_1178646917713491">17</xref> Nicotinamide adenine dinucleotide can be synthesized through niacin, which is typically present in an adequate diet<xref ref-type="bibr" rid="b2-10.1177_1178646917713491">2</xref>,<xref ref-type="bibr" rid="b87-10.1177_1178646917713491">87</xref>,<xref ref-type="bibr" rid="b94-10.1177_1178646917713491">94</xref> and is the main source of NAD<sup>+</sup> synthesis or de novo through tryptophan and the kynurenine pathway.<xref ref-type="bibr" rid="b27-10.1177_1178646917713491">27</xref>,<xref ref-type="bibr" rid="b95-10.1177_1178646917713491">95</xref></p>
<p><italic>De novo</italic> synthesis of NAD<sup>+</sup> starts with the catalysis of tryptophan by either TDO-2 or IDO-1<xref ref-type="bibr" rid="b95-10.1177_1178646917713491">95</xref> into formylkynurenine followed by conversion into <sc>l</sc>-kynurenine. Three more enzymatic reactions described elsewhere<xref ref-type="bibr" rid="b9-10.1177_1178646917713491">9</xref> lead to the conversion into 2-amino-3-carboxymuconate semialdehyde (ACMS). ACMS can go either through an enzymatic pathway leading to total oxidation or through a nonenzymatic cyclization to QUIN. QUIN is essential for <italic>de novo</italic> synthesis of NAD<sup>+</sup>.<xref ref-type="bibr" rid="b17-10.1177_1178646917713491">17</xref>,<xref ref-type="bibr" rid="b87-10.1177_1178646917713491">87</xref> Interestingly, QUIN has been shown to be neurotoxic.<xref ref-type="bibr" rid="b28-10.1177_1178646917713491">28</xref>,<xref ref-type="bibr" rid="b96-10.1177_1178646917713491">96</xref> Moreover, QUIN accumulates in human glioma cells and is associated with malignant phenotypes.<xref ref-type="bibr" rid="b97-10.1177_1178646917713491">97</xref> Furthermore, QUIN was found to confer resistance of gliomas to oxidative stress. The cytotoxic properties of QUIN in the brain have extensively been discussed in the literature, but very little is known about its role in immune responses. Nicotinamide adenine dinucleotide has been found to induce programmed cell death and hinder Tregs.<xref ref-type="bibr" rid="b98-10.1177_1178646917713491">98</xref>,<xref ref-type="bibr" rid="b99-10.1177_1178646917713491">99</xref> Although we were able to confirm that NAD<sup>+</sup> induces apoptosis of naïve CD4<sup>+</sup> T-cells and reduces the number of Tregs,<xref ref-type="bibr" rid="b29-10.1177_1178646917713491">29</xref> CD4<sup>+</sup> T-cells that were differentiated into T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17, and iTreg were protected against apoptosis by NAD<sup>+</sup>.</p>
<p>Our previous studies showed the importance of the tryptophan/NAD<sup>+</sup> pathway in inflammation, including autoimmune diseases and transplantation. These studies were performed in the context of antigen and antigen presentation. Our unpublished data indicate that the NAD<sup>+</sup>/tryptophan signaling pathway can trigger innate and adaptive immune responses in the absence of antigen. This is consistent with previous studies reporting that tryptophan administration promotes wound healing.<xref ref-type="bibr" rid="b100-10.1177_1178646917713491">100</xref> However, the effects of exogenous tryptophan in immune responses have not been well studied. Interestingly, a previous study by Swanson et al<xref ref-type="bibr" rid="b101-10.1177_1178646917713491">101</xref> showed that exogenous addition of tryptophan to recover lung interstitial antigen-presenting cells (APCs)–induced T-cell proliferation in mixed leukocyte reactions. Of note, the addition of exogenous tryptophan can restore pathogens and replication of some bacteria and viruses<xref ref-type="bibr" rid="b43-10.1177_1178646917713491">43</xref>; thus, further studies are required to elucidate the role of exogenous tryptophan in immune responses.</p>
<p>Antigen-presenting cells play a unique role in the regulation of adaptive immune responses due to their ability to capture, process, and present antigens via their major histocompatibility complex (MHC) cell surface molecule to the T-cell receptor (TCR) to mount a restricted MHC immune response.<xref ref-type="bibr" rid="b102-10.1177_1178646917713491">102</xref>–<xref ref-type="bibr" rid="b104-10.1177_1178646917713491">104</xref> DCs are still considered the major APCs bridging innate and adaptive immune responses.<xref ref-type="bibr" rid="b105-10.1177_1178646917713491">105</xref>,<xref ref-type="bibr" rid="b106-10.1177_1178646917713491">106</xref> The mode of action of DCs is mediated through at least 3 signals: (1) TCR activation, (2) activation of co-stimulatory molecules, and (3) secretion of chemokines and pro-inflammatory cytokines.<xref ref-type="bibr" rid="b105-10.1177_1178646917713491">105</xref> In addition, DCs can regulate innate and adaptive immune responses by recognizing pathogen-associated molecular patterns, such as microbial nucleic acids, lipoproteins, and carbohydrates, or damage-associated molecular patterns that are released from injured cells via intracellular or surface-expressed pattern recognition receptors (PRRs).<xref ref-type="bibr" rid="b107-10.1177_1178646917713491">107</xref> Thus, our unpublished data, indicating that the tryptophan/NAD<sup>+</sup> pathway can trigger the immune system in the absence of pathogen invasion or PRRs’ activation, suggest a novel cellular and molecular signaling pathway distinct from the classical ag-APCs (DCs)-MHCII-TCR signaling machinery. It would therefore be interesting to further investigate the path used by tryptophan/NAD<sup>+</sup>, particularly the cells and molecules involved.</p>
</sec>
<sec>
<title>Tryptophan and NAD<sup>+</sup> in the CNS</title>
<p>Active interactions between the CNS and the immune system are essential to maintain CNS integrity and homeostasis. The intact blood-brain barrier allows traffic of peripheral immune cells, CNS neurons and glia regulate macrophage and lymphocyte responses, and microglia play key roles in both innate and adaptive immune responses, providing the CNS with the strategic means to respond to pathogens. Thus, the past 30 years have seen significant changes in notions of CNS immune privilege. The immune implications of tryptophan have begun to extend into the CNS as well. Tryptophan is also the sole precursor of an important neurotransmitter, serotonin, or 5-hydroxytryptophan. Serotonin is synthesized from tryptophan through hydroxylation and decarboxylation, processes that are catalyzed by tryptophan hydroxylase (Tph) and the aromatic acid decarboxylase, with Tph being the rate-limiting step in the synthesis. Of the 2 isoforms of Tph, Tph1 is expressed both in the periphery (skin, enterochromaffin cells of the gut, mast cells, and the pineal gland) and in the CNS, and Tph2 is expressed in neurons of the central, peripheral, and enteric nervous systems. Indeed, <italic>tph1</italic>-null mice have gross abnormalities such as an overall size reduction, altered morphology of the rhombencephalon regions and neopallial cortex, alterations in gait dynamics, and reduced motivation locomotion.<xref ref-type="bibr" rid="b108-10.1177_1178646917713491">108</xref>
<italic>Tph2</italic>-null mice show alterations in developmental milestones, brain-to-body weight ratio, and substantial deficits in numerous validated tests of social interaction and communication with highly repetitive and compulsive behaviors.<xref ref-type="bibr" rid="b109-10.1177_1178646917713491">109</xref> There appears to be no substantial overlap in the expression of the 2 <italic>tph</italic> isoforms by adulthood. Dietary tryptophan can also regulate serotonin synthesis in the brain and can affect mood, behavior, and cognition. Serotonin synthesis is thus an important tryptophan pathway and is a topic of intense research due to its broad impact as a neuromodulator. Multiple lines of evidence support its association with numerous neuropsychiatric conditions such as Parkinson disease, schizophrenia, depression, anxiety, and, of great significance, autism.</p>
<p>Autism, which is characterized as both a neurodevelopmental and a neuropsychiatric disease, has also distinctly evolved into a disease of the immune system.<xref ref-type="bibr" rid="b110-10.1177_1178646917713491">110</xref>–<xref ref-type="bibr" rid="b112-10.1177_1178646917713491">112</xref> One or more core behavioral symptoms, such as impaired social recognition, reduced social interactions, communication deficits, increased anxiety, motor stereotypies, repetitive behaviors, insistence on sameness, and restricted interests, identify autism. The Centers for Disease Control and Prevention estimates that ~1 in 88 children is diagnosed with autism each year, more than those diagnosed annually with cancer, diabetes, and AIDS combined. Currently, approximately $35 billion in direct and indirect care costs are spent annually for autism.<xref ref-type="bibr" rid="b113-10.1177_1178646917713491">113</xref> The annual cost of caring for patients with autism is believed to reach $500 billion by 2025, with outside estimates reaching $1 trillion.<xref ref-type="bibr" rid="b114-10.1177_1178646917713491">114</xref> Therefore, it is critical to gain mechanistic insights into multiple pathways coexisting in autism that will lay the foundation for new therapeutic opportunities.</p>
<p>Close associations between the serotonin and kynurenic pathways occur in tryptophan metabolism that are strongly influenced by the activity of the immune system. Quinolinic acid, a downstream product of the kynurenic pathway, is the structural precursor of NAD<sup>+</sup>, a critical energy carrier in mitochondria. Therefore, decreased tryptophan metabolism via either serotonin or QUIN will alter brain development, neuroimmune activity, and mitochondrial function. Interestingly, decreased tryptophan metabolism affecting both serotonin and kynurenic pathways has been linked to autism. Even a short-term reduction in the levels of tryptophan exacerbates repetitive, compulsive behaviors (eg, flapping, rocking, and whirling) in drug-free adults with autism.<xref ref-type="bibr" rid="b115-10.1177_1178646917713491">115</xref> Serotonin in the blood is stored in platelets that undergo endocytosis via the serotonin transporter. Abnormal blood levels of serotonin produce autistic-like behaviors, such as impaired social communication and avoidance of new situations.<xref ref-type="bibr" rid="b116-10.1177_1178646917713491">116</xref> Children with autism show a diminished capacity of whole-brain or regional brain serotonin synthesis that affects language production and sensory integration.<xref ref-type="bibr" rid="b117-10.1177_1178646917713491">117</xref>,<xref ref-type="bibr" rid="b118-10.1177_1178646917713491">118</xref> There are reports of reductions in not only serotonin concentrations but also the kynurenic acid levels in the cerebrospinal fluid of autistic children.<xref ref-type="bibr" rid="b119-10.1177_1178646917713491">119</xref>,<xref ref-type="bibr" rid="b120-10.1177_1178646917713491">120</xref> Diminished levels of NAD<sup>+</sup> and plasma tryptophan in parallel with increased levels of oxidative stress have been reported in children with autism.<xref ref-type="bibr" rid="b121-10.1177_1178646917713491">121</xref>,<xref ref-type="bibr" rid="b122-10.1177_1178646917713491">122</xref> In addition, urinary levels of tryptophan are reduced in patients with autism.<xref ref-type="bibr" rid="b123-10.1177_1178646917713491">123</xref></p>
<p>Taken together, these results illustrate the critical need for a better understanding of the detailed mechanistic actions of tryptophan and NAD<sup>+</sup> from cellular, molecular, and immunologic perspectives at distinct developmental time points in the CNS, which will aid in designing novel treatment strategies and bring new hope for neuroimmunological diseases such as autism. In addition, changes in tryptophan metabolism and pathway intermediates may serve in the development of new diagnostic assays for CNS immunologic disorders.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>Increasing evidence indicates the important role of tryptophan catabolism in immune responses via the kynurenine pathway <italic>in vivo</italic>.<xref ref-type="bibr" rid="b51-10.1177_1178646917713491">51</xref>,<xref ref-type="bibr" rid="b124-10.1177_1178646917713491">124</xref>,<xref ref-type="bibr" rid="b125-10.1177_1178646917713491">125</xref> However, the exact mechanisms remain unknown. Based on the findings shown here, NAD<sup>+</sup> might be responsible for the newly found functions of tryptophan in immune responses. In particular, <italic>de novo</italic> synthesis of NAD<sup>+</sup> through QUIN, one of the catabolites of the kynurenine pathway, appears to have an important role in immune regulation and tolerance (<xref ref-type="fig" rid="f1-10.1177_1178646917713491">Figure 1</xref>). However, tryptophan catabolites appear to have contradictory functions, depending on where they are involved and warrant further investigation. Furthermore, mast cells, although they are not typical APCs, might play an important role in the tryptophan/QUIN/NAD<sup>+</sup> pathway regulating T-cell activation. Clearly, the field of immunology shaped by tryptophan and NAD<sup>+</sup> is poised for several exciting discoveries in the future.</p>
</sec>
</body>
<back>
<fn-group>
<fn id="fn4-10.1177_1178646917713491">
<p><bold>FUNDING:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was funded by the “Queen Elizabeth Hospital Birmingham (QEHB) Charity.”</p>
</fn>
<fn id="fn1-10.1177_1178646917713491">
<p><bold>PEER REVIEW:</bold> Six peer reviewers contributed to the peer review report. Reviewers’ reports totaled 1714 words, excluding any confidential comments to the academic editor.</p>
</fn>
<fn fn-type="COI-statement" id="fn2-10.1177_1178646917713491">
<p><bold>DECLARATION OF CONFLICTING INTERESTS:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn id="fn3-10.1177_1178646917713491">
<p>
<bold>Author Contributions</bold>
</p>
<p>Conceived the concepts: HRCB, AE. Wrote or contributed to the writing of the manuscript: HRCB, AV, AE. Made critical revisions: AV, AE. Reviewed and approved the final manuscript: HRCB, AE.</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="b1-10.1177_1178646917713491">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopkins</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>A contribution to the chemistry of proteids: part I. A preliminary study of a hitherto undescribed product of tryptic digestion</article-title>
<source/>J Physiol (Lond)
          <year>1901</year>
<volume>27</volume>
<fpage>418</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="pmid">16992614</pub-id>
</element-citation>
</ref>
<ref id="b2-10.1177_1178646917713491">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richard</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Dawes</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mathias</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Acheson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hill-Kapturczak</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dougherty</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications</article-title>
<source/>Int J Tryptophan Res
          <year>2009</year>
<volume>2</volume>
<fpage>45</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">20651948</pub-id>
</element-citation>
</ref>
<ref id="b3-10.1177_1178646917713491">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orhan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sandberg</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor stimulation in peripheral monocytes</article-title>
<source/>Scand J Immunol
          <year>2016</year>
<volume>84</volume>
<fpage>262</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="pmid">27607184</pub-id>
</element-citation>
</ref>
<ref id="b4-10.1177_1178646917713491">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bender</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Biochemistry of tryptophan in health and disease</article-title>
<source/>Mol Aspects Med
          <year>1983</year>
<volume>6</volume>
<fpage>101</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="pmid">6371429</pub-id>
</element-citation>
</ref>
<ref id="b5-10.1177_1178646917713491">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blankfield</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A brief historic overview of clinical disorders associated with tryptophan: the relevance to chronic fatigue syndrome (CFS) and fibromyalgia (FM)</article-title>
<source/>Int J Tryptophan Res
          <year>2012</year>
<volume>5</volume>
<fpage>27</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">23032646</pub-id>
</element-citation>
</ref>
<ref id="b6-10.1177_1178646917713491">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lichters</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brunnlieb</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nave</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The influence of serotonin deficiency on choice deferral and the compromise effect</article-title>
<source/>J Marketing Res
          <year>2016</year>
<volume>53</volume>
<fpage>183</fpage>
<lpage>198</lpage>
</element-citation>
</ref>
<ref id="b7-10.1177_1178646917713491">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>Aspects of tryptophan metabolism in health and disease: a review</article-title>
<source/>J Clin Pathol
          <year>1972</year>
<volume>25</volume>
<fpage>17</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">4552476</pub-id>
</element-citation>
</ref>
<ref id="b8-10.1177_1178646917713491">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gracia-Rubio</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Moscoso-Castro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pozo</surname>
<given-names>OJ</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nadal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Valverde</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Maternal separation induces neuroinflammation and long-lasting emotional alterations in mice</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2016</year>
<volume>65</volume>
<fpage>104</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="pmid">26382758</pub-id>
</element-citation>
</ref>
<ref id="b9-10.1177_1178646917713491">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Braidy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bessesde</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The kynurenine pathway in brain tumor pathogenesis</article-title>
<source/>Cancer Res
          <year>2012</year>
<volume>72</volume>
<fpage>5649</fpage>
<lpage>5657</lpage>
<pub-id pub-id-type="pmid">23144293</pub-id>
</element-citation>
</ref>
<ref id="b10-10.1177_1178646917713491">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilotte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Larrieu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stroobant</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<fpage>2497</fpage>
<lpage>2502</lpage>
<pub-id pub-id-type="pmid">22308364</pub-id>
</element-citation>
</ref>
<ref id="b11-10.1177_1178646917713491">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puccetti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fallarino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Italiano</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<fpage>e0122046</fpage>
<pub-id pub-id-type="pmid">25881064</pub-id>
</element-citation>
</ref>
<ref id="b12-10.1177_1178646917713491">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schultze</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>IDO-expressing regulatory dendritic cells in cancer and chronic infection</article-title>
<source/>J Mol Med
          <year>2008</year>
<volume>86</volume>
<fpage>145</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="pmid">17876564</pub-id>
</element-citation>
</ref>
<ref id="b13-10.1177_1178646917713491">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Platten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wick</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Van den Eynde</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion</article-title>
<source/>Cancer Res
          <year>2012</year>
<volume>72</volume>
<fpage>5435</fpage>
<lpage>5440</lpage>
<pub-id pub-id-type="pmid">23090118</pub-id>
</element-citation>
</ref>
<ref id="b14-10.1177_1178646917713491">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Macleod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chandler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Munn</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Tryptophan deprivation sensitizes activated T-cells to apoptosis prior to cell division</article-title>
<source/>Immunology
          <year>2002</year>
<volume>107</volume>
<fpage>452</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">12460190</pub-id>
</element-citation>
</ref>
<ref id="b15-10.1177_1178646917713491">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushwah</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Role of dendritic cells in the induction of regulatory T-cells</article-title>
<source/>Cell Biosci
          <year>2010</year>
<volume>1</volume>
<fpage>20</fpage>
</element-citation>
</ref>
<ref id="b16-10.1177_1178646917713491">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maldonado</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>von Andrian</surname>
<given-names>UH</given-names>
</name>
</person-group>
<article-title>How tolerogenic dendritic cells induce regulatory T-cells</article-title>
<source/>Adv Immunol
          <year>2009</year>
<volume>108</volume>
<fpage>111</fpage>
<lpage>165</lpage>
</element-citation>
</ref>
<ref id="b17-10.1177_1178646917713491">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moffett</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Namboodiri</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Tryptophan and the immune response</article-title>
<source/>Immunol Cell Biol
          <year>2003</year>
<volume>81</volume>
<fpage>247</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="pmid">12848846</pub-id>
</element-citation>
</ref>
<ref id="b18-10.1177_1178646917713491">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation</article-title>
<source/>Front Biosci
          <year>2015</year>
<volume>20</volume>
<fpage>1116</fpage>
<lpage>1143</lpage>
</element-citation>
</ref>
<ref id="b19-10.1177_1178646917713491">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pertovaara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raitala</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uusitalo</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjogren’s syndrome</article-title>
<source/>Clin Exp Immunol
          <year>2005</year>
<volume>142</volume>
<fpage>155</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="pmid">16178870</pub-id>
</element-citation>
</ref>
<ref id="b20-10.1177_1178646917713491">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Baren</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Van den Eynde</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Tumoral immune resistance mediated by enzymes that degrade tryptophan</article-title>
<source/>Cancer Immunol Res
          <year>2015</year>
<volume>3</volume>
<fpage>978</fpage>
<lpage>985</lpage>
<pub-id pub-id-type="pmid">26269528</pub-id>
</element-citation>
</ref>
<ref id="b21-10.1177_1178646917713491">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schröcksnadel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wirleitner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Monitoring tryptophan metabolism in chronic immune activation</article-title>
<source/>Clin Chim Acta
          <year>2006</year>
<volume>364</volume>
<fpage>82</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">16139256</pub-id>
</element-citation>
</ref>
<ref id="b22-10.1177_1178646917713491">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The kynurenine pathway in stem cell biology</article-title>
<source/>Int J Tryptophan Res
          <year>2013</year>
<volume>6</volume>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">24092986</pub-id>
</element-citation>
</ref>
<ref id="b23-10.1177_1178646917713491">
<label>23</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Michelhaugh</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Varadarajan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Guastella</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Mittal</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Role of kynurenine pathway in neuro-oncology</article-title>
<person-group person-group-type="editor">
<name>
<surname>Mittal</surname>
<given-names>S</given-names>
</name>
</person-group>
<source/>Targeting the Broadly Pathogenic Kynurenine Pathway
          <publisher-loc>Cham</publisher-loc>
<publisher-name>Springer International Publishing</publisher-name>
<year>2015</year>
<fpage>287</fpage>
<lpage>295</lpage>
</element-citation>
</ref>
<ref id="b24-10.1177_1178646917713491">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grant</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Passey</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matanovic</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Smythe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism?</article-title>
<source/>Arch Biochem Biophys
          <year>1999</year>
<volume>372</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">10562410</pub-id>
</element-citation>
</ref>
<ref id="b25-10.1177_1178646917713491">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Sudar</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>NA</given-names>
</name>
</person-group>
<article-title>Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase</article-title>
<source/>Biochem Biophys Res Commun
          <year>1986</year>
<volume>134</volume>
<fpage>227</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="pmid">3080986</pub-id>
</element-citation>
</ref>
<ref id="b26-10.1177_1178646917713491">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ramírez-Hernández</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The new life of a centenarian: signalling functions of NAD(P)</article-title>
<source/>Trends Biochem Sci
          <year>2004</year>
<volume>29</volume>
<fpage>111</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">15003268</pub-id>
</element-citation>
</ref>
<ref id="b27-10.1177_1178646917713491">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Effects of kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons</article-title>
<source/>Int J Tryptophan Res
          <year>2011</year>
<volume>4</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">22084601</pub-id>
</element-citation>
</ref>
<ref id="b28-10.1177_1178646917713491">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guillemin</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Quinolinic acid, the inescapable neurotoxin</article-title>
<source/>FEBS J
          <year>2012</year>
<volume>279</volume>
<fpage>1356</fpage>
<lpage>1365</lpage>
<pub-id pub-id-type="pmid">22248144</pub-id>
</element-citation>
</ref>
<ref id="b29-10.1177_1178646917713491">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tullius</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Cetina Biefer</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NAD+ protects against EAE by regulating CD4+ T-cell differentiation</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>5101</fpage>
<pub-id pub-id-type="pmid">25290058</pub-id>
</element-citation>
</ref>
<ref id="b30-10.1177_1178646917713491">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elkhal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cetina Biefer</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Heinbokel</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NAD+ regulates Treg cell fate and promotes allograft survival via a systemic IL-10 production that is CD4+ CD25+ Foxp3+ T-cells independent</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>22325</fpage>
<pub-id pub-id-type="pmid">26928119</pub-id>
</element-citation>
</ref>
<ref id="b31-10.1177_1178646917713491">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment with NAD+ inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice</article-title>
<source/>Int Immunopharmacol
          <year>2016</year>
<volume>39</volume>
<fpage>287</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="pmid">27500459</pub-id>
</element-citation>
</ref>
<ref id="b32-10.1177_1178646917713491">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>HC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor</article-title>
<source/>Allergy
          <year>2014</year>
<volume>69</volume>
<fpage>445</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">24397465</pub-id>
</element-citation>
</ref>
<ref id="b33-10.1177_1178646917713491">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>XC</given-names>
</name>
</person-group>
<article-title>IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T-cells</article-title>
<source/>Transpl Immunol
          <year>2015</year>
<volume>33</volume>
<fpage>69</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">26002283</pub-id>
</element-citation>
</ref>
<ref id="b34-10.1177_1178646917713491">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uyttenhove</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pilotte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Théate</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</article-title>
<source/>Nat Med
          <year>2003</year>
<volume>9</volume>
<fpage>1269</fpage>
<lpage>1274</lpage>
<pub-id pub-id-type="pmid">14502282</pub-id>
</element-citation>
</ref>
<ref id="b35-10.1177_1178646917713491">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G-X</given-names>
</name>
<name>
<surname>Gran</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IDO upregulates regulatory T-cells via tryptophan catabolite and suppresses encephalitogenic T-cell responses in experimental autoimmune encephalomyelitis</article-title>
<source/>J Immunol
          <year>2010</year>
<volume>185</volume>
<fpage>5953</fpage>
<lpage>5961</lpage>
<pub-id pub-id-type="pmid">20944000</pub-id>
</element-citation>
</ref>
<ref id="b36-10.1177_1178646917713491">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stockinger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Meglio</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Gialitakis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>The aryl hydrocarbon receptor: multitasking in the immune system</article-title>
<source/>Annu Rev Immunol
          <year>2014</year>
<volume>32</volume>
<fpage>403</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="pmid">24655296</pub-id>
</element-citation>
</ref>
<ref id="b37-10.1177_1178646917713491">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quintana</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Sherr</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Aryl hydrocarbon receptor control of adaptive immunity</article-title>
<source/>Pharmacol Rev
          <year>2013</year>
<volume>65</volume>
<fpage>1148</fpage>
<lpage>1161</lpage>
<pub-id pub-id-type="pmid">23908379</pub-id>
</element-citation>
</ref>
<ref id="b38-10.1177_1178646917713491">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quintana</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<article-title>The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response</article-title>
<source/>Immunology
          <year>2013</year>
<volume>138</volume>
<fpage>183</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="pmid">23190340</pub-id>
</element-citation>
</ref>
<ref id="b39-10.1177_1178646917713491">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apetoh</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Quintana</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Pot</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T-cells induced by IL-27</article-title>
<source/>Nat Immunol
          <year>2010</year>
<volume>11</volume>
<fpage>854</fpage>
<lpage>861</lpage>
<pub-id pub-id-type="pmid">20676095</pub-id>
</element-citation>
</ref>
<ref id="b40-10.1177_1178646917713491">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandhi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>EJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T-cell-like and Foxp3+ regulatory T-cells</article-title>
<source/>Nat Immunol
          <year>2010</year>
<volume>11</volume>
<fpage>846</fpage>
<lpage>853</lpage>
<pub-id pub-id-type="pmid">20676092</pub-id>
</element-citation>
</ref>
<ref id="b41-10.1177_1178646917713491">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quintana</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Basso</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Iglesias</surname>
<given-names>AH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor</article-title>
<source/>Nature
          <year>2008</year>
<volume>453</volume>
<fpage>65</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">18362915</pub-id>
</element-citation>
</ref>
<ref id="b42-10.1177_1178646917713491">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>ACF</given-names>
</name>
<name>
<surname>Pinho</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>de Moraes</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Bergami-Santos</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Barbuto</surname>
<given-names>JAM</given-names>
</name>
</person-group>
<article-title>Tolerogenic IDO(+) dendritic cells are induced by PD-1-expressing mast cells</article-title>
<source/>Front Immunol
          <year>2016</year>
<volume>7</volume>
<fpage>9</fpage>
<pub-id pub-id-type="pmid">26834749</pub-id>
</element-citation>
</ref>
<ref id="b43-10.1177_1178646917713491">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellor</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Munn</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>IDO expression by dendritic cells: tolerance and tryptophan catabolism</article-title>
<source/>Nat Rev Immunol
          <year>2004</year>
<volume>4</volume>
<fpage>762</fpage>
<lpage>774</lpage>
<pub-id pub-id-type="pmid">15459668</pub-id>
</element-citation>
</ref>
<ref id="b44-10.1177_1178646917713491">
<label>44</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Engin</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Evaluation of tryptophan metabolism in chronic immune activation</article-title>
<person-group person-group-type="editor">
<name>
<surname>Engin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Engin</surname>
<given-names>AB</given-names>
</name>
</person-group>
<source/><italic>Tryptophan Metabolism: Implications for Biological Processes, Health and Disease</italic> (Molecular and Integrative Toxicology)
          <publisher-loc>Cham, Switzerland</publisher-loc>
<publisher-name>Springer International Publishing</publisher-name>
<year>2015</year>
<fpage>121</fpage>
<lpage>145</lpage>
</element-citation>
</ref>
<ref id="b45-10.1177_1178646917713491">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opitz</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Litzenburger</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Sahm</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor</article-title>
<source/>Nature
          <year>2011</year>
<volume>478</volume>
<fpage>197</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">21976023</pub-id>
</element-citation>
</ref>
<ref id="b46-10.1177_1178646917713491">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lemos</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Mautino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases</article-title>
<source/>Front Immunol
          <year>2012</year>
<volume>3</volume>
<fpage>109</fpage>
<pub-id pub-id-type="pmid">22593757</pub-id>
</element-citation>
</ref>
<ref id="b47-10.1177_1178646917713491">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puccetti</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>On the non-redundant roles of TDO2 and IDO1</article-title>
<source/>Front Immunol
          <year>2014</year>
<volume>5</volume>
<fpage>522</fpage>
<pub-id pub-id-type="pmid">25368621</pub-id>
</element-citation>
</ref>
<ref id="b48-10.1177_1178646917713491">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulain-Godefroy</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Eury</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leloire</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induction of TDO2 and IDO2 in liver by high-fat feeding in mice: discrepancies with human obesity</article-title>
<source/>Int J Tryptophan Res
          <year>2013</year>
<volume>6</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">26882470</pub-id>
</element-citation>
</ref>
<ref id="b49-10.1177_1178646917713491">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Amato</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer</article-title>
<source/>Cancer Res
          <year>2015</year>
<volume>75</volume>
<fpage>4651</fpage>
<lpage>4664</lpage>
<pub-id pub-id-type="pmid">26363006</pub-id>
</element-citation>
</ref>
<ref id="b50-10.1177_1178646917713491">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novikov</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Stanford</surname>
<given-names>EA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/PR-/Her2- human breast cancer cells</article-title>
<source/>Mol Pharmacol
          <year>2016</year>
<volume>90</volume>
<fpage>674</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="pmid">27573671</pub-id>
</element-citation>
</ref>
<ref id="b51-10.1177_1178646917713491">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>Y-L</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>J-Y</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>S-Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>27584</fpage>
<lpage>27598</lpage>
<pub-id pub-id-type="pmid">27050278</pub-id>
</element-citation>
</ref>
<ref id="b52-10.1177_1178646917713491">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crosignani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Driessens</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Detheux</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van den Eynde</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cauwenberghs</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Preclinical assessment of a novel small molecule inhibitor of tryptophan 2,3-di-oxygenase 2 (TDO2)</article-title>
<source/>J Immunother Cancer
          <year>2014</year>
<volume>2</volume>
<fpage>196</fpage>
</element-citation>
</ref>
<ref id="b53-10.1177_1178646917713491">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>NP-Y</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JK-Y</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>Indoleamine 2,3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines</article-title>
<source/>Cell Res
          <year>2005</year>
<volume>15</volume>
<fpage>167</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="pmid">15780178</pub-id>
</element-citation>
</ref>
<ref id="b54-10.1177_1178646917713491">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miwa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion</article-title>
<source/>Mol Hum Reprod
          <year>2005</year>
<volume>11</volume>
<fpage>865</fpage>
<lpage>870</lpage>
<pub-id pub-id-type="pmid">16421220</pub-id>
</element-citation>
</ref>
<ref id="b55-10.1177_1178646917713491">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takikawa</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism</article-title>
<source/>Biochem Bioph Res Co
          <year>2005</year>
<volume>338</volume>
<fpage>12</fpage>
<lpage>19</lpage>
</element-citation>
</ref>
<ref id="b56-10.1177_1178646917713491">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujigaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takemura</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes</article-title>
<source/>Arch Biochem Biophys
          <year>1998</year>
<volume>358</volume>
<fpage>329</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">9784247</pub-id>
</element-citation>
</ref>
<ref id="b57-10.1177_1178646917713491">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werner-Felmayer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hausen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reibnegger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wachter</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Characteristics of interferon induced tryptophan metabolism in human cells in vitro</article-title>
<source/>Biochim Biophys Acta
          <year>1989</year>
<volume>1012</volume>
<fpage>140</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">2500976</pub-id>
</element-citation>
</ref>
<ref id="b58-10.1177_1178646917713491">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha</article-title>
<source/>J Biol Chem
          <year>1990</year>
<volume>265</volume>
<fpage>19871</fpage>
<lpage>19877</lpage>
<pub-id pub-id-type="pmid">2174056</pub-id>
</element-citation>
</ref>
<ref id="b59-10.1177_1178646917713491">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tanguy Royer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Royer</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IDO expands human CD4+CD25high regulatory T-cells by promoting maturation of LPS-treated dendritic cells</article-title>
<source/>Eur J Immunol
          <year>2007</year>
<volume>37</volume>
<fpage>3054</fpage>
<lpage>3062</lpage>
<pub-id pub-id-type="pmid">17948274</pub-id>
</element-citation>
</ref>
<ref id="b60-10.1177_1178646917713491">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sioud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nyakas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sæbøe-Larssen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mobergslien</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aamdal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kvalheim</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine</article-title>
<source/>Case Rep Med
          <year>2016</year>
<volume>2016</volume>
<fpage>9639585</fpage>
<pub-id pub-id-type="pmid">27504122</pub-id>
</element-citation>
</ref>
<ref id="b61-10.1177_1178646917713491">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Koropatnick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model</article-title>
<source/>Int J Cancer
          <year>2013</year>
<volume>132</volume>
<fpage>967</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="pmid">22870862</pub-id>
</element-citation>
</ref>
<ref id="b62-10.1177_1178646917713491">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamahira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Narita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iwabuchi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of the leukemia plasmacytoid dendritic cell line PMDC05 by Toho-1, a novel IDO inhibitor</article-title>
<source/>Anticancer Res
          <year>2014</year>
<volume>34</volume>
<fpage>4021</fpage>
<lpage>4028</lpage>
<pub-id pub-id-type="pmid">25075025</pub-id>
</element-citation>
</ref>
<ref id="b63-10.1177_1178646917713491">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X-F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H-S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells</article-title>
<source/>Cell Immunol
          <year>2014</year>
<volume>289</volume>
<fpage>42</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">24721110</pub-id>
</element-citation>
</ref>
<ref id="b64-10.1177_1178646917713491">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prendergast</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>IDO recruits Tregs in melanoma</article-title>
<source/>Cell Cycle
          <year>2009</year>
<volume>8</volume>
<fpage>1818</fpage>
<lpage>1819</lpage>
<pub-id pub-id-type="pmid">19471123</pub-id>
</element-citation>
</ref>
<ref id="b65-10.1177_1178646917713491">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wainwright</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lesniak</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Targeting Tregs in malignant brain cancer: overcoming IDO</article-title>
<source/>Front Immunol
          <year>2013</year>
<volume>4</volume>
<fpage>116</fpage>
<pub-id pub-id-type="pmid">23720663</pub-id>
</element-citation>
</ref>
<ref id="b66-10.1177_1178646917713491">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>NW</given-names>
</name>
</person-group>
<article-title>Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder</article-title>
<source/>Int J Tryptophan Res
          <year>2010</year>
<volume>3</volume>
<fpage>121</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">22084594</pub-id>
</element-citation>
</ref>
<ref id="b67-10.1177_1178646917713491">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haarmann-Stemmann</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>An introduction to the molecular basics of aryl hydrocarbon receptor biology</article-title>
<source/>Biol Chem
          <year>2010</year>
<volume>391</volume>
<fpage>1235</fpage>
<lpage>1248</lpage>
<pub-id pub-id-type="pmid">20868221</pub-id>
</element-citation>
</ref>
<ref id="b68-10.1177_1178646917713491">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mimura</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor</article-title>
<source/>Genes Cells
          <year>1997</year>
<volume>2</volume>
<fpage>645</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="pmid">9427285</pub-id>
</element-citation>
</ref>
<ref id="b69-10.1177_1178646917713491">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Oppenheim</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Th17 cells and Tregs: unlikely allies</article-title>
<source/>J Leukoc Biol
          <year>2014</year>
<volume>95</volume>
<fpage>723</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="pmid">24563509</pub-id>
</element-citation>
</ref>
<ref id="b70-10.1177_1178646917713491">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The yin and yang of signaling in Tregs and TH17 cells</article-title>
<source/>Sci Signal
          <year>2011</year>
<volume>4</volume>
<fpage>mr4</fpage>
<pub-id pub-id-type="pmid">21427407</pub-id>
</element-citation>
</ref>
<ref id="b71-10.1177_1178646917713491">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kipnis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dessein</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Bacterial modulation of Tregs/Th17 in intestinal disease: a balancing act?</article-title>
<source/>Inflamm Bowel Dis
          <year>2012</year>
<volume>18</volume>
<fpage>1389</fpage>
<lpage>1390</lpage>
<pub-id pub-id-type="pmid">22114034</pub-id>
</element-citation>
</ref>
<ref id="b72-10.1177_1178646917713491">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swain</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>McKinstry</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Strutt</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Expanding roles for CD4+ T-cells in immunity to viruses</article-title>
<source/>Nat Rev Immunol
          <year>2012</year>
<volume>12</volume>
<fpage>136</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">22266691</pub-id>
</element-citation>
</ref>
<ref id="b73-10.1177_1178646917713491">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A complex issue on CD4(+) T-cell subsets</article-title>
<source/>Immunol Rev
          <year>2013</year>
<volume>252</volume>
<fpage>5</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">23405891</pub-id>
</element-citation>
</ref>
<ref id="b74-10.1177_1178646917713491">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mehling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Loeser</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells</article-title>
<source/>Nat Med
          <year>2006</year>
<volume>12</volume>
<fpage>1372</fpage>
<lpage>1379</lpage>
<pub-id pub-id-type="pmid">17143276</pub-id>
</element-citation>
</ref>
<ref id="b75-10.1177_1178646917713491">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fritsche</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Calles</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2007</year>
<volume>104</volume>
<fpage>8851</fpage>
<lpage>8856</lpage>
<pub-id pub-id-type="pmid">17502624</pub-id>
</element-citation>
</ref>
<ref id="b76-10.1177_1178646917713491">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases</article-title>
<source/>Cell Mol Immunol
          <year>2015</year>
<volume>12</volume>
<fpage>533</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">25958843</pub-id>
</element-citation>
</ref>
<ref id="b77-10.1177_1178646917713491">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duarte</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Di Meglio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hirota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ahlfors</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stockinger</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<fpage>e79819</fpage>
<pub-id pub-id-type="pmid">24244565</pub-id>
</element-citation>
</ref>
<ref id="b78-10.1177_1178646917713491">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voo</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y-H</given-names>
</name>
<name>
<surname>Santori</surname>
<given-names>FR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of IL-17-producing FOXP3+ regulatory T-cells in humans</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2009</year>
<volume>106</volume>
<fpage>4793</fpage>
<lpage>4798</lpage>
<pub-id pub-id-type="pmid">19273860</pub-id>
</element-citation>
</ref>
<ref id="b79-10.1177_1178646917713491">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komatsu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pathogenic conversion of Foxp3+ T-cells into TH17 cells in autoimmune arthritis</article-title>
<source/>Nat Med
          <year>2014</year>
<volume>20</volume>
<fpage>62</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">24362934</pub-id>
</element-citation>
</ref>
<ref id="b80-10.1177_1178646917713491">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roncarolo</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Gregori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Battaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bacchetta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fleischhauer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Levings</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Interleukin-10-secreting type 1 regulatory T-cells in rodents and humans</article-title>
<source/>Immunol Rev
          <year>2006</year>
<volume>212</volume>
<fpage>28</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">16903904</pub-id>
</element-citation>
</ref>
<ref id="b81-10.1177_1178646917713491">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Awasthi</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells</article-title>
<source/>J Immunol
          <year>2009</year>
<volume>183</volume>
<fpage>797</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="pmid">19570826</pub-id>
</element-citation>
</ref>
<ref id="b82-10.1177_1178646917713491">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rink</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Uciechowski</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The Th17/Treg balance is disturbed during aging</article-title>
<source/>Exp Gerontol
          <year>2013</year>
<volume>48</volume>
<fpage>1379</fpage>
<lpage>1386</lpage>
<pub-id pub-id-type="pmid">24055797</pub-id>
</element-citation>
</ref>
<ref id="b83-10.1177_1178646917713491">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chalaris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmidt-Arras</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rose-John</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The pro- and anti-inflammatory properties of the cytokine interleukin-6</article-title>
<source/>Biochim Biophys Acta
          <year>2011</year>
<volume>1813</volume>
<fpage>878</fpage>
<lpage>888</lpage>
<pub-id pub-id-type="pmid">21296109</pub-id>
</element-citation>
</ref>
<ref id="b84-10.1177_1178646917713491">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jordan</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interleukin 6 (IL-6) a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade</article-title>
<source/>Transplantation
          <year>2017</year>
<volume>101</volume>
<fpage>32</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">27547870</pub-id>
</element-citation>
</ref>
<ref id="b85-10.1177_1178646917713491">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carpenter</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Gawuga</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Tyrka</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>LH</given-names>
</name>
</person-group>
<article-title>Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults</article-title>
<source/>Neuropsychopharmacology
          <year>2010</year>
<volume>35</volume>
<fpage>2617</fpage>
<lpage>2623</lpage>
<pub-id pub-id-type="pmid">20881945</pub-id>
</element-citation>
</ref>
<ref id="b86-10.1177_1178646917713491">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bessede</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gargaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pallotta</surname>
<given-names>MT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aryl hydrocarbon receptor control of a disease tolerance defence pathway</article-title>
<source/>Nature
          <year>2014</year>
<volume>511</volume>
<fpage>184</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="pmid">24930766</pub-id>
</element-citation>
</ref>
<ref id="b87-10.1177_1178646917713491">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantó</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Menzies</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus</article-title>
<source/>Cell Metab
          <year>2015</year>
<volume>22</volume>
<fpage>31</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">26118927</pub-id>
</element-citation>
</ref>
<ref id="b88-10.1177_1178646917713491">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harden</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>The alcoholic ferment of yeast-juice</article-title>
<source/>P Roy Soc B: Biol Sci
          <year>1906</year>
<volume>77</volume>
<fpage>405</fpage>
<lpage>420</lpage>
</element-citation>
</ref>
<ref id="b89-10.1177_1178646917713491">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Subash</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Braidy</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of NAD+, oxidative stress, and tryptophan metabolism in autism spectrum disorders</article-title>
<source/>Int J Tryptophan Res
          <year>2013</year>
<fpage>15</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">23922500</pub-id>
</element-citation>
</ref>
<ref id="b90-10.1177_1178646917713491">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>NAD+ and NADH in ischemic brain injury</article-title>
<source/>Front Biosci
          <year>2008</year>
<volume>13</volume>
<fpage>1141</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="pmid">17981619</pub-id>
</element-citation>
</ref>
<ref id="b91-10.1177_1178646917713491">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruzzone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fruscione</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Morando</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE</article-title>
<source/>PLoS ONE
          <year>2009</year>
<volume>4</volume>
<fpage>e7897</fpage>
<pub-id pub-id-type="pmid">19936064</pub-id>
</element-citation>
</ref>
<ref id="b92-10.1177_1178646917713491">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Gool</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gueydan</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner</article-title>
<source/>Nat Med
          <year>2009</year>
<volume>15</volume>
<fpage>206</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">19151729</pub-id>
</element-citation>
</ref>
<ref id="b93-10.1177_1178646917713491">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braidy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jayasena</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Effects of kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons</article-title>
<source/>Int J Tryptophan Res
          <year>2009</year>
<volume>2</volume>
<fpage>61</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">22084582</pub-id>
</element-citation>
</ref>
<ref id="b94-10.1177_1178646917713491">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurnasov</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Goral</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Colabroy</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria</article-title>
<source/>Chem Biol
          <year>2002</year>
<volume>10</volume>
<fpage>1195</fpage>
<lpage>1204</lpage>
</element-citation>
</ref>
<ref id="b95-10.1177_1178646917713491">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houtkooper</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Cantó</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wanders</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways</article-title>
<source/>Endocr Rev
          <year>2010</year>
<volume>31</volume>
<fpage>194</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">20007326</pub-id>
</element-citation>
</ref>
<ref id="b96-10.1177_1178646917713491">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarcz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Whetsell</surname>
<given-names>WO</given-names>
</name>
<name>
<surname>Mangano</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain</article-title>
<source/>Science
          <year>1983</year>
<volume>219</volume>
<fpage>316</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="pmid">6849138</pub-id>
</element-citation>
</ref>
<ref id="b97-10.1177_1178646917713491">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahm</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Oezen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Opitz</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative Stress</article-title>
<source/>Cancer Res
          <year>2013</year>
<volume>73</volume>
<fpage>3225</fpage>
<lpage>3234</lpage>
<pub-id pub-id-type="pmid">23548271</pub-id>
</element-citation>
</ref>
<ref id="b98-10.1177_1178646917713491">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adriouch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haag</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Seman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koch-Nolte</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Extracellular NAD+: a danger signal hindering regulatory T-cells</article-title>
<source/>Microbes Infect
          <year>2012</year>
<volume>14</volume>
<fpage>1284</fpage>
<lpage>1292</lpage>
<pub-id pub-id-type="pmid">22634347</pub-id>
</element-citation>
</ref>
<ref id="b99-10.1177_1178646917713491">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adriouch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hubert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pechberty</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koch-Nolte</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Haag</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Seman</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>NAD+ released during inflammation participates in T-cell homeostasis by inducing ART2-mediated death of naive T-cells in vivo</article-title>
<source/>J Immunol
          <year>2007</year>
<volume>179</volume>
<fpage>186</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="pmid">17579037</pub-id>
</element-citation>
</ref>
<ref id="b100-10.1177_1178646917713491">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bandeira</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Bortolot</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Cecatto</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Monte-Alto-Costa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Romana-Souza</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Exogenous tryptophan promotes cutaneous wound healing of chronically stressed mice through inhibition of TNF-α and IDO activation</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<fpage>e0128439</fpage>
<pub-id pub-id-type="pmid">26057238</pub-id>
</element-citation>
</ref>
<ref id="b101-10.1177_1178646917713491">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Heidler</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Mizobuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wilkes</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>CDIIc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-di-oxygenase</article-title>
<source/>Am J Resp Cell Mol
          <year>2004</year>
<volume>30</volume>
<fpage>311</fpage>
<lpage>318</lpage>
</element-citation>
</ref>
<ref id="b102-10.1177_1178646917713491">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zinkernagel</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>The discovery of MHC restriction</article-title>
<source/>Immunol Today
          <year>1997</year>
<volume>18</volume>
<fpage>14</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">9018968</pub-id>
</element-citation>
</ref>
<ref id="b103-10.1177_1178646917713491">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haskins</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>White</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pigeon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kappler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marrack</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The major histocompatibility complex-restricted antigen receptor on T-cells. I. Isolation with a monoclonal antibody</article-title>
<source/>J Exp Med
          <year>1983</year>
<volume>157</volume>
<fpage>1149</fpage>
<lpage>1169</lpage>
<pub-id pub-id-type="pmid">6601175</pub-id>
</element-citation>
</ref>
<ref id="b104-10.1177_1178646917713491">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Exley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terhorst</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wileman</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Structure, assembly and intracellular transport of the T-cell receptor for antigen</article-title>
<source/>Semin Immunol
          <year>1991</year>
<volume>3</volume>
<fpage>283</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="pmid">1686832</pub-id>
</element-citation>
</ref>
<ref id="b105-10.1177_1178646917713491">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemos</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Esquivel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Laufer</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>MHC class II expression restricted to CD8alpha+ and CD11b+ dendritic cells is sufficient for control of <italic>Leishmania major</italic></article-title>
<source/>J Exp Med
          <year>2004</year>
<volume>199</volume>
<fpage>725</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="pmid">14993255</pub-id>
</element-citation>
</ref>
<ref id="b106-10.1177_1178646917713491">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kambayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Laufer</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?</article-title>
<source/>Nat Rev Immunol
          <year>2014</year>
<volume>14</volume>
<fpage>719</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="pmid">25324123</pub-id>
</element-citation>
</ref>
<ref id="b107-10.1177_1178646917713491">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Medzhitov</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Control of adaptive immunity by the innate immune system</article-title>
<source/>Nat Immunol
          <year>2015</year>
<volume>16</volume>
<fpage>343</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="pmid">25789684</pub-id>
</element-citation>
</ref>
<ref id="b108-10.1177_1178646917713491">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suidan</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Duerschmied</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dillon</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lack of tryptophan hydroxylase-1 in mice results in gait abnormalities</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<fpage>e59032</fpage>
<pub-id pub-id-type="pmid">23516593</pub-id>
</element-citation>
</ref>
<ref id="b109-10.1177_1178646917713491">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kane</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Angoa-Peréz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>DI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to autism</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<fpage>e48975</fpage>
<pub-id pub-id-type="pmid">23139830</pub-id>
</element-citation>
</ref>
<ref id="b110-10.1177_1178646917713491">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrahams</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Advances in autism genetics: on the threshold of a new neurobiology</article-title>
<source/>Nat Rev Genet
          <year>2008</year>
<volume>9</volume>
<fpage>341</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="pmid">18414403</pub-id>
</element-citation>
</ref>
<ref id="b111-10.1177_1178646917713491">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Behavioural phenotyping assays for mouse models of autism</article-title>
<source/>Nat Rev Neurosci
          <year>2010</year>
<volume>11</volume>
<fpage>490</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="pmid">20559336</pub-id>
</element-citation>
</ref>
<ref id="b112-10.1177_1178646917713491">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Immunity, neuroglia and neuroin-flammation in autism</article-title>
<source/>Int Rev Psychiatry
          <year>2005</year>
<volume>17</volume>
<fpage>485</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="pmid">16401547</pub-id>
</element-citation>
</ref>
<ref id="b113-10.1177_1178646917713491">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganz</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>The lifetime distribution of the incremental societal costs of autism</article-title>
<source/>Arch Pediatr Adolesc Med
          <year>2007</year>
<volume>161</volume>
<fpage>343</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="pmid">17404130</pub-id>
</element-citation>
</ref>
<ref id="b114-10.1177_1178646917713491">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tipton</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Blacher</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Brief report: autism awareness: views from a campus community</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<fpage>477</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">23881093</pub-id>
</element-citation>
</ref>
<ref id="b115-10.1177_1178646917713491">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Aghajanian</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Heninger</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>LH</given-names>
</name>
</person-group>
<article-title>Effects of tryptophan depletion in drug-free adults with autistic disorder</article-title>
<source/>Arch Gen Psychiatry
          <year>1996</year>
<volume>53</volume>
<fpage>993</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="pmid">8911222</pub-id>
</element-citation>
</ref>
<ref id="b116-10.1177_1178646917713491">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Philippe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bouvard</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives</article-title>
<source/>Biol Psychiatry
          <year>1999</year>
<volume>45</volume>
<fpage>158</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">9951562</pub-id>
</element-citation>
</ref>
<ref id="b117-10.1177_1178646917713491">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugani</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Muzik</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rothermel</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys</article-title>
<source/>Ann Neurol
          <year>1997</year>
<volume>42</volume>
<fpage>666</fpage>
<lpage>669</lpage>
<pub-id pub-id-type="pmid">9382481</pub-id>
</element-citation>
</ref>
<ref id="b118-10.1177_1178646917713491">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugani</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Muzik</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Behen</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children</article-title>
<source/>Ann Neurol
          <year>1999</year>
<volume>45</volume>
<fpage>287</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="pmid">10072042</pub-id>
</element-citation>
</ref>
<ref id="b119-10.1177_1178646917713491">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamsen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramaekers</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>HT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene</article-title>
<source/>Mol Autism
          <year>2014</year>
<volume>5</volume>
<fpage>43</fpage>
<pub-id pub-id-type="pmid">25802735</pub-id>
</element-citation>
</ref>
<ref id="b120-10.1177_1178646917713491">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Comi</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebrospinal fluid and serum markers of inflammation in autism</article-title>
<source/>Pediatr Neurol
          <year>2005</year>
<volume>33</volume>
<fpage>195</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">16139734</pub-id>
</element-citation>
</ref>
<ref id="b121-10.1177_1178646917713491">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Audhya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McDonough-Means</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nutritional and metabolic status of children with autism vs neurotypical children, and the association with autism severity</article-title>
<source/>Nutr Metab (Lond)
          <year>2011</year>
<volume>8</volume>
<fpage>34</fpage>
<pub-id pub-id-type="pmid">21651783</pub-id>
</element-citation>
</ref>
<ref id="b122-10.1177_1178646917713491">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Braidy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Waly</surname>
<given-names>MI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired antioxidant status and reduced energy metabolism in autistic children</article-title>
<source/>Res Autism Spect Dis
          <year>2013</year>
<volume>7</volume>
<fpage>557</fpage>
<lpage>565</lpage>
</element-citation>
</ref>
<ref id="b123-10.1177_1178646917713491">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kałuzna-Czaplinska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Michalska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rynkowski</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Determination of tryptophan in urine of autistic and healthy children by gas chromatography/mass spectrometry</article-title>
<source/>Med Sci Monit
          <year>2010</year>
<volume>16</volume>
<fpage>CR488</fpage>
<lpage>CR492</lpage>
<pub-id pub-id-type="pmid">20885353</pub-id>
</element-citation>
</ref>
<ref id="b124-10.1177_1178646917713491">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munn</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Shafizadeh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Attwood</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Bondarev</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pashine</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Inhibition of T-cell proliferation by macrophage tryptophan catabolism</article-title>
<source/>J Exp Med
          <year>1999</year>
<volume>189</volume>
<fpage>1363</fpage>
<lpage>1372</lpage>
<pub-id pub-id-type="pmid">10224276</pub-id>
</element-citation>
</ref>
<ref id="b125-10.1177_1178646917713491">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Zaatari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y-M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tryptophan catabolism restricts IFN-γ-expressing neutrophils and <italic>Clostridium difficile</italic> immunopathology</article-title>
<source/>J Immunol
          <year>2014</year>
<volume>193</volume>
<fpage>807</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="pmid">24935925</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-10.1177_1178646917713491" position="float">
<label>Figure 1</label>
<caption>
<p>Newfound functions of tryptophan in immune responses might be influenced by NAD+. De novo synthesis of NAD+ through QUIN appears to have an important role in immune regulation and tolerance. CNS indicates central nervous system; IDO, indoleamine 2,3-dyoxygenase; <italic>KYNp</italic>, kynurenine pathway; NAD+, nicotinamide adenine dinucleotide; QUIN, quinolinic acid; TDO, tryptophan 2,3-dyoxygenase; Tph1, tryptophan hydroxylase 1; Tph2, tryptophan hydroxylase 2; Tregs, regulatory T-cells; TRP, tryptophan.</p>
</caption>
<graphic xlink:href="10.1177_1178646917713491-fig1"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>